Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May:202:107336.
doi: 10.1016/j.eplepsyres.2024.107336. Epub 2024 Mar 2.

Epilepsy in neurofibromatosis type 1: Prevalence, phenotype, and genotype in adults

Julien Hébert  1 , Robert J De Santis  2 , Lubna Daniyal  3 , Shabber Mannan  3 , Eduardo Ng  3 , Emily Thain  4 , Maria Carolina Sanabria-Salas  5 , Raymond H Kim  6 , Vera Bril  7 , Aylin Y Reid  8
Affiliations
Free article

Epilepsy in neurofibromatosis type 1: Prevalence, phenotype, and genotype in adults

Julien Hébert et al. Epilepsy Res. 2024 May.
Free article

Abstract

Purpose: Studies have shown an increased risk of epilepsy in patients with neurofibromatosis type 1 (NF1). However, most reports focus on the pediatric population. In this study, we describe the trajectory of patients with NF1 and epilepsy beyond childhood.

Methods: Patients with NF1 ≥18 years-old consecutively seen at a multidisciplinary neurofibromatosis clinic during a four-year period were prospectively enrolled and offered routine EEG, MRI, and genetic testing. The lifelong and point prevalence of epilepsy in patients with NF1 were calculated. Demographic, genetic, radiological, and clinical features found to be statistically associated with having received a diagnosis of epilepsy were incorporated into a logistic regression model.

Results: Among 113 patients with NF1 included in this study (median age at study inclusion: 33 years), the lifelong prevalence of epilepsy was 11% (CI95%=6-18%) and point prevalence 7% (CI95%= 3-13%). Most patients (73%) were diagnosed with epilepsy before the age of 18 and achieved seizure-freedom by adulthood. At study inclusion, three-quarters of patients with a diagnosis of epilepsy had been seizure-free for more than one year and a third had resolved epilepsy. A routine EEG with epileptiform discharges had a sensitivity of 25% (CI95%=3-65) and specificity of 99% (CI95%=93-100) for identifying adult patients with NF1 and unresolved epilepsy. A history of epilepsy was associated with having a low-grade glioma (OR: 38.2; CI95%=2.2-674.7; p<0.01), learning disability (OR: 5.7; CI95%=1.0-31.5; p<0.05), and no plexiform neurofibroma (OR: 0.05; CI95%=0.0-0.8; p=0.04). No single mutation type was associated with the development of epilepsy.

Conclusions: In patients with NF1, although resolution of epilepsy over time was observed in many cases, the prevalence of epilepsy was higher among adults with NF1 than that reported in the general population. Epileptogenesis in NF1 likely requires the combination of multiple genetic and environmental factors and suggests involvement of a network that spreads beyond the borders of a well-defined parenchymal lesion.

Keywords: Clinical epidemiology; Electroencephalogram; Epilepsy; Genetics; Neurocutaneous disorder; Neurofibromatosis.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest JH received salary support through a grant from the American Epilepsy Society while working on this manuscript. AYR received project funding through the Toronto General and Western Hospital Foundation.

Publication types